D-arabinose synthesis in TB using Azorhizobium as a tool
Project Number1R03TW006237-01
Contact PI/Project LeaderMCNEIL, MICHAEL R
Awardee OrganizationCOLORADO STATE UNIVERSITY
Description
Abstract Text
DESCRIPTION (provided by applicant): Tuberculosis is a major opportunistic disease of AIDS which exacerbates the course of the illness. Furthermore, tuberculosis threatens AIDS caretakers and contacts and breeds drugs resistant strains of M. tuberculosis. Hence, new drugs, specific for M. tuberculosis are needed to help control the AIDS epidemic. D-arabinose formation is an ideal TB drug target as it is essential and specific for M. tuberculosis and D-arabinose is not found in humans. The pathway for formation of D-arabinose in M. tuberculosis has been determined by the PI; however, the genes have not been successfully identified. Thus, the purpose of this AIDS-FIRCA research is to identify the M. tuberculosis genes responsible for the synthesis of D-arabinose and determine the function of the encoded proteins. The breakthrough that has made both this research and the collaboration possible is the finding by the foreign collaborator, Dr. Holsters, of four genes in Azorhizobium caulinodans that synthesize D-arabinose (A. caulinodans is one of the very few other organisms in nature that synthesize D-arabinose besides mycobacteria). Furthermore, she discovered the existence of genes in M. tuberculosis homologous to three of the A. caulinodans genes. Therefore, we propose to identify the D-arabinose synthetic genes in M. tuberculosis by complementing specific gene knockout mutants of A. caulinodans with M. tuberculosis gene candidates. Further we propose to determine the function of each gene product by the identification of D-arabinose formation precursors in these specific gene knockout strains of A. caulinodans and by expression and enzymatic assay of the M. tuberculosis and A. caulinodans genes in E. coli. The genetics on A. caulinodans and the searches for D-arabinose precursors will be mostly performed at the foreign site while needed radioactive precursors and biochemical techniques and genetics in mycobacteria will come from the American site.
John E. Fogarty International Center for Advanced Study in the Health Sciences
CFDA Code
934
DUNS Number
785979618
UEI
LT9CXX8L19G1
Project Start Date
15-February-2003
Project End Date
31-January-2006
Budget Start Date
15-February-2003
Budget End Date
31-January-2004
Project Funding Information for 2003
Total Funding
$39,540
Direct Costs
$32,000
Indirect Costs
$7,540
Year
Funding IC
FY Total Cost by IC
2003
John E. Fogarty International Center for Advanced Study in the Health Sciences
$39,540
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R03TW006237-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R03TW006237-01
Patents
No Patents information available for 1R03TW006237-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R03TW006237-01
Clinical Studies
No Clinical Studies information available for 1R03TW006237-01
News and More
Related News Releases
No news release information available for 1R03TW006237-01
History
No Historical information available for 1R03TW006237-01
Similar Projects
No Similar Projects information available for 1R03TW006237-01